HRP20120657T1 - Farmaceutski pripravak 271 - Google Patents

Farmaceutski pripravak 271 Download PDF

Info

Publication number: HRP20120657T1
Authority: HR; Croatia
Prior art keywords: pharmaceutical preparation; preparation according; benzoimidazole; phenylamino; bromo
Prior art date: 2008-03-28

Application number

HRP20120657AT

Other languages

English (en)

Croatian (hr)

Inventor

Frances Bateman Nicola

Richard Gellert Paul

Jane Hill Kathryn

Original Assignee

Astrazeneca Ab

Array Biopharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-28

Filing date

2009-03-26

Publication date

2012-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120657(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-26 Application filed by Astrazeneca Ab, Array Biopharma filed Critical Astrazeneca Ab

2012-09-30 Publication of HRP20120657T1 publication Critical patent/HRP20120657T1/hr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Inorganic Chemistry (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Obesity (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

HRP20120657AT 2008-03-28 2009-03-26 Farmaceutski pripravak 271 HRP20120657T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4037208P	2008-03-28	2008-03-28
PCT/GB2009/050293 WO2009118562A1 (en)	2008-03-28	2009-03-26	Pharmaceutical composition 271

Publications (1)

Publication Number	Publication Date
HRP20120657T1 true HRP20120657T1 (hr)	2012-09-30

Family

ID=40792932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20120657AT HRP20120657T1 (hr)	2008-03-28	2009-03-26	Farmaceutski pripravak 271

Country Status (30)

Country	Link
US (12)	US20090246274A1 (pt)
EP (1)	EP2271321B1 (pt)
JP (2)	JP5547710B2 (pt)
KR (1)	KR101650958B1 (pt)
CN (1)	CN102046156B (pt)
AR (2)	AR071100A1 (pt)
AU (1)	AU2009229204B2 (pt)
BR (1)	BRPI0909267B8 (pt)
CA (1)	CA2718653C (pt)
CL (1)	CL2009000765A1 (pt)
CO (1)	CO6311068A2 (pt)
CY (1)	CY1113279T1 (pt)
DK (1)	DK2271321T3 (pt)
EC (1)	ECSP10010578A (pt)
ES (1)	ES2387942T3 (pt)
HR (1)	HRP20120657T1 (pt)
IL (1)	IL208206A0 (pt)
MX (1)	MX2010010671A (pt)
MY (1)	MY157492A (pt)
NZ (1)	NZ588849A (pt)
PE (1)	PE20091755A1 (pt)
PL (1)	PL2271321T3 (pt)
PT (1)	PT2271321E (pt)
RS (1)	RS52409B (pt)
SA (1)	SA109300195B1 (pt)
TW (1)	TWI433840B (pt)
UA (1)	UA101654C2 (pt)
UY (1)	UY31737A (pt)
WO (1)	WO2009118562A1 (pt)
ZA (1)	ZA201006766B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
RS55764B1 (sr)	2012-10-02	2017-07-31	Gilead Sciences	Inhibitori histonskih demetilaza
CA2901022C (en)	2013-02-27	2021-05-04	Epitherapeutics Aps	Substituted pyridine compounds as inhibitors of histone demethylases
EP3126345A1 (en)	2014-03-31	2017-02-08	Gilead Sciences, Inc.	Inhibitors of histone demethylases
SG11201701182VA (en)	2014-08-27	2017-03-30	Gilead Sciences Inc	Compounds and methods for inhibiting histone demethylases
CN121443286A (zh) *	2023-05-25	2026-01-30	地图之光治疗股份有限公司	用于治疗神经障碍的组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6022852A (en)	1993-10-22	2000-02-08	Hexal Ag	Pharmaceutical composition containing cyclosporin A
BR9507437A (pt)	1994-04-07	1997-09-16	Smithkline Beecham Plc	Base livre de halofantrina e composições para o tratamento da malária
WO1996036316A1 (en)	1995-05-19	1996-11-21	Abbott Laboratories	Self-emulsifying formulations of lipophilic drugs
BE1009856A5 (fr)	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
MY126358A (en) *	1996-03-22	2006-09-29	Glaxo Group Ltd	Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5891469A (en)	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
EP1331002A3 (en)	1997-01-30	2004-01-14	Novartis AG	Oil-free pharmaceutical compositions containing cyclosporin A
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
US20030104048A1 (en)	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6372251B2 (en)	1999-06-11	2002-04-16	Abbott Laboratories	Formulations comprising lipid-regulating agents
US20030236236A1 (en)	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ITMI20011337A1 (it)	2001-06-26	2002-12-26	Farmatron Ltd	Composizioni farmaceutiche orali a rilascio modificato del principio attivo
WO2004026235A2 (en)	2002-09-20	2004-04-01	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
WO2004000284A1 (en) *	2002-06-21	2003-12-31	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
SG2013013339A (en)	2002-03-13	2014-12-30	Array Biopharma Inc	N3 alkylated benzimidazole derivatives as mek inhibitors
US20040127551A1 (en)	2002-12-27	2004-07-01	Kai Zhang	Taxane-based compositions and methods of use
KR20090080143A (ko) *	2003-09-02	2009-07-23	화이자 프로덕츠 인크.	지프라시돈의 지속 방출형 투여 형태
US20050096365A1 (en)	2003-11-03	2005-05-05	David Fikstad	Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en)	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
AR046773A1 (es)	2003-12-23	2005-12-21	Novartis Ag	Formulaciones farmaceuticas de bisfosfonatos
CA2552925A1 (en)	2004-01-30	2005-08-18	Pfizer Italia S.R.L.	Semisolid matrix pharmaceutical formulations
KR20050104152A (ko) *	2004-04-28	2005-11-02	최승호	경구용 약물의 흡수를 증진하는 약제학적 조성물
WO2006138431A2 (en)	2005-06-16	2006-12-28	Eastman Chemical Company	Methods and pharmaceutical formulations for increasing bioavailability
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US9561178B2 (en)	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
WO2009117151A2 (en)	2008-03-20	2009-09-24	Virun, Inc.	Compositions containing non-polar compounds
SA109300195B1 (ar) *	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان

2009
- 2009-03-25 SA SA109300195A patent/SA109300195B1/ar unknown
- 2009-03-26 JP JP2011501300A patent/JP5547710B2/ja active Active
- 2009-03-26 RS RS20120357A patent/RS52409B/sr unknown
- 2009-03-26 UY UY0001031737A patent/UY31737A/es not_active Application Discontinuation
- 2009-03-26 TW TW098109981A patent/TWI433840B/zh active
- 2009-03-26 WO PCT/GB2009/050293 patent/WO2009118562A1/en not_active Ceased
- 2009-03-26 MY MYPI2010004504A patent/MY157492A/en unknown
- 2009-03-26 CN CN200980120227.7A patent/CN102046156B/zh active Active
- 2009-03-26 AU AU2009229204A patent/AU2009229204B2/en active Active
- 2009-03-26 EP EP09726304A patent/EP2271321B1/en active Active
- 2009-03-26 HR HRP20120657AT patent/HRP20120657T1/hr unknown
- 2009-03-26 KR KR1020107023140A patent/KR101650958B1/ko active Active
- 2009-03-26 ES ES09726304T patent/ES2387942T3/es active Active
- 2009-03-26 MX MX2010010671A patent/MX2010010671A/es active IP Right Grant
- 2009-03-26 DK DK09726304.0T patent/DK2271321T3/da active
- 2009-03-26 US US12/411,865 patent/US20090246274A1/en not_active Abandoned
- 2009-03-26 CA CA2718653A patent/CA2718653C/en active Active
- 2009-03-26 PL PL09726304T patent/PL2271321T3/pl unknown
- 2009-03-26 BR BRPI0909267A patent/BRPI0909267B8/pt active IP Right Grant
- 2009-03-26 PT PT09726304T patent/PT2271321E/pt unknown
- 2009-03-26 NZ NZ588849A patent/NZ588849A/en unknown
- 2009-03-26 UA UAA201012519A patent/UA101654C2/uk unknown
- 2009-03-27 CL CL2009000765A patent/CL2009000765A1/es unknown
- 2009-03-27 PE PE2009000461A patent/PE20091755A1/es not_active Application Discontinuation
- 2009-03-27 AR ARP090101107A patent/AR071100A1/es not_active Application Discontinuation
2010
- 2010-09-16 IL IL208206A patent/IL208206A0/en active IP Right Grant
- 2010-09-21 ZA ZA2010/06766A patent/ZA201006766B/en unknown
- 2010-10-28 CO CO10134209A patent/CO6311068A2/es active IP Right Grant
- 2010-10-28 EC EC2010010578A patent/ECSP10010578A/es unknown
2011
- 2011-11-10 US US13/293,368 patent/US20120114750A1/en not_active Abandoned
2012
- 2012-08-13 CY CY20121100732T patent/CY1113279T1/el unknown
2013
- 2013-01-23 US US13/747,853 patent/US20130195971A1/en not_active Abandoned
2014
- 2014-02-17 JP JP2014027398A patent/JP2014114320A/ja active Pending
2015
- 2015-10-15 US US14/884,343 patent/US20160030574A1/en not_active Abandoned
2016
- 2016-11-10 US US15/348,053 patent/US20170056375A1/en not_active Abandoned
2018
- 2018-06-29 US US16/023,102 patent/US20190030004A1/en not_active Abandoned
2019
- 2019-08-23 AR ARP190102398A patent/AR116001A2/es not_active Application Discontinuation
- 2019-10-09 US US16/597,237 patent/US20200179344A1/en not_active Abandoned
2021
- 2021-05-06 US US17/313,312 patent/US11813246B2/en active Active
2023
- 2023-10-10 US US18/484,334 patent/US12220403B2/en active Active
- 2023-10-10 US US18/484,337 patent/US12465593B2/en active Active
2024
- 2024-09-03 US US18/823,257 patent/US12318367B2/en active Active
- 2024-09-03 US US18/823,274 patent/US12364684B2/en active Active

Also Published As

Publication number	Publication date
JP2014114320A (ja)	2014-06-26
BRPI0909267A2 (pt)	2017-05-30
US20200179344A1 (en)	2020-06-11
US20220087982A1 (en)	2022-03-24
US12318367B2 (en)	2025-06-03
CA2718653C (en)	2016-02-09
US12220403B2 (en)	2025-02-11
US20240041835A1 (en)	2024-02-08
US11813246B2 (en)	2023-11-14
US12465593B2 (en)	2025-11-11
AU2009229204A1 (en)	2009-10-01
EP2271321A1 (en)	2011-01-12
RS52409B (sr)	2013-02-28
DK2271321T3 (da)	2012-08-27
US20130195971A1 (en)	2013-08-01
ECSP10010578A (es)	2010-11-30
CN102046156B (zh)	2014-12-17
US20250000848A1 (en)	2025-01-02
KR20110005246A (ko)	2011-01-17
MX2010010671A (es)	2011-06-20
AU2009229204B2 (en)	2012-05-24
HK1149476A1 (en)	2011-10-07
AR116001A2 (es)	2021-03-25
NZ588849A (en)	2012-06-29
JP5547710B2 (ja)	2014-07-16
CO6311068A2 (es)	2011-08-22
US20170056375A1 (en)	2017-03-02
US20240041834A1 (en)	2024-02-08
BRPI0909267B1 (pt)	2020-07-07
UY31737A (es)	2009-11-10
IL208206A0 (en)	2010-12-30
ES2387942T3 (es)	2012-10-04
PT2271321E (pt)	2012-08-16
EP2271321B1 (en)	2012-06-13
ZA201006766B (en)	2011-05-25
TW200946511A (en)	2009-11-16
AR071100A1 (es)	2010-05-26
SA109300195B1 (ar)	2013-04-20
UA101654C2 (uk)	2013-04-25
US12364684B2 (en)	2025-07-22
MY157492A (en)	2016-06-15
BRPI0909267B8 (pt)	2021-05-25
WO2009118562A1 (en)	2009-10-01
TWI433840B (zh)	2014-04-11
JP2011515455A (ja)	2011-05-19
CN102046156A (zh)	2011-05-04
US20120114750A1 (en)	2012-05-10
KR101650958B1 (ko)	2016-08-24
CL2009000765A1 (es)	2011-02-11
HK1156844A1 (zh)	2012-06-22
PE20091755A1 (es)	2009-12-13
US20090246274A1 (en)	2009-10-01
CA2718653A1 (en)	2009-10-01
RU2491920C2 (ru)	2013-09-10
US20190030004A1 (en)	2019-01-31
US20160030574A1 (en)	2016-02-04
RU2010143906A (ru)	2012-05-10
CY1113279T1 (el)	2016-04-13
PL2271321T3 (pl)	2013-03-29
US20240423960A1 (en)	2024-12-26

Publication	Publication Date	Title
HRP20120657T1 (hr)	2012-09-30	Farmaceutski pripravak 271
Kaur et al.	2020	Memantine nanoemulsion: A new approach to treat Alzheimer’s disease
ES2802252T3 (es)	2021-01-18	Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
Xu et al.	2021	Alginate nanogels-based thermosensitive hydrogel to improve antidepressant-like effects of albiflorin via intranasal delivery
FI3725778T4 (fi)	2026-03-11	Entsalutamidiformulaatioita
HRP20201048T1 (hr)	2020-10-16	Farmaceutska formulacija koja sadrži inozitol
PH12014502271A1 (en)	2014-12-10	Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
MY157697A (en)	2016-07-15	Reverse-phase microcapsules for active ingredients, simplified process of manufacture thereof and combined formulations wdg-cs, zc, ec-sc and cx
JP2012236834A5 (pt)	2013-01-24
ES2983643T3 (es)	2024-10-24	Terapia oral con tridecanoato de testosterona
CN102188384A (zh)	2011-09-21	调控利培酮微球释放行为和控制微球尺寸大小的制备微球方法
PH12014502609B1 (en)	2015-01-21	Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
ITMI20072051A1 (it)	2009-04-24	Composizione a base di pellet di acido lipoico
CN103830201A (zh)	2014-06-04	一种度他雄胺液体软胶囊
Geronimo et al.	2021	Development of S 75: R 25 bupivacaine‐loaded lipid nanoparticles functionalized with essential oils for treating melanoma
Guo et al.	2025	Immunostimulatory hydrogel with synergistic blockage of glutamine metabolism and chemodynamic therapy for postoperative management of glioblastoma
Zhang et al.	2023	Emerging anesthetic nanomedicines: Current state and challenges
CA2880945C (en)	2016-10-11	2,2',6,6'-tetraisopropyl-4,4'-biphenol soft capsule and method for preparing the same
CN101953798A (zh)	2011-01-26	一种含丹皮酚的喷雾干燥缓释液晶纳米粒及其制备
CN102886047A (zh)	2013-01-23	黄芩素组合物及其制备方法
CN102488207A (zh)	2012-06-13	一种辅酶q10软胶囊及其制备方法
EA201100616A1 (ru)	2012-02-28	Новые формы применения цинеола
Xie et al.	2017	Preparation and evaluation of 131I-quercetin as a novel radiotherapy agent against dedifferentiated thyroid cancer
ITMI20010220A1 (it)	2002-08-05	Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
CN107789444A (zh)	2018-03-13	一种宠物犬亮毛维生素软胶囊组方及其制备方法